Eli Lilly Non-GAAP EPS of $3.92 beats by $1.16, revenue of $11.3B beats by $1.33B
by
Contributor since / Followers
Contributor since / Followers
5 months ago
- Eli Lilly press release (NYSE:LLY): Q2 Non-GAAP EPS of $3.92 beats by $1.16.
- Revenue of $11.3B (+36.0% Y/Y) beats by $1.33B.
- Revenue in Q2 2024 increased 36%, driven by Mounjaro, Zepbound and Verzenio. When excluding $579.0 million of revenue from the sale of rights for Baqsimi in Q2 2023, revenue in Q2 2024 increased 46%. Excluding the sale of rights for Baqsimi, non-incretin revenue increased 17% worldwide and 25% in the U.S.
- FY24 revenue consensus of $42.95B, EPS consensus of $13.71
-
The following table summarizes the company’s 2024 financial guidance:
2024 Guidance
Prior
Updated
Revenue
$42.4 to $43.6 billion
$45.4 to $46.6 billion
(Gross Margin – OPEX) / Revenue:
(reported)
32% to 34%
36% to 38%
(non-GAAP)
33% to 35%
37% to 39%
Other Income/(Expense) (reported)
($500) to ($400) million
($525) to ($425) million
Other Income/(Expense) (non-GAAP)
($500) to ($400) million
($400) to ($300) million
Tax Rate
Approx. 14%
Approx. 15%
Earnings per Share (reported)
$13.05 to $13.55
$15.10 to $15.60
Earnings per Share (non-GAAP)
$13.50 to $14.00
$16.10 to $16.60